John C Byrd1, Bonnie Harrington, Susan O'Brien, Jeffrey A Jones, Anna Schuh, Steve Devereux, Jorge Chaves, William G Wierda, Farrukh T Awan, Jennifer R Brown, Peter Hillmen, Deborah M Stephens, Paolo Ghia, Jacqueline C Barrientos, John M Pagel, Jennifer Woyach, Dave Johnson, Jane Huang, Xiaolin Wang, Allard Kaptein, Brian J Lannutti, Todd Covey, Maria Fardis, Jesse McGreivy, Ahmed Hamdy, Wayne Rothbaum, Raquel Izumi, Thomas G Diacovo, Amy J Johnson, Richard R Furman. 1. From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).
Abstract
BACKGROUND: Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors. METHODS: In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion. RESULTS: The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated immunoglobulin heavy-chain variable genes. No dose-limiting toxic effects occurred during the dose-escalation portion of the study. The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), and increased weight (in 26%). Most adverse events were of grade 1 or 2. At a median follow-up of 14.3 months, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease. Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%. No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred. CONCLUSIONS: In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).
BACKGROUND: Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL). However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index. Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors. METHODS: In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib. Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion. RESULTS: The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated immunoglobulin heavy-chain variable genes. No dose-limiting toxic effects occurred during the dose-escalation portion of the study. The most common adverse events observed were headache (in 43% of the patients), diarrhea (in 39%), and increased weight (in 26%). Most adverse events were of grade 1 or 2. At a median follow-up of 14.3 months, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease. Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%. No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred. CONCLUSIONS: In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion. (Funded by the Acerta Pharma and others; ClinicalTrials.gov number, NCT02029443.).
Authors: Jennifer R Brown; Wael A Harb; Brian T Hill; Janice Gabrilove; Jeff P Sharman; Marshall T Schreeder; Paul M Barr; James M Foran; Thomas P Miller; Jan A Burger; Kevin R Kelly; Daruka Mahadevan; Shuo Ma; Yan Li; Daniel W Pierce; Evelyn Barnett; Jeffrey Marine; Monika Miranda; Ada Azaryan; Xujie Yu; Pilar Nava-Parada; Jay Mei; Thomas J Kipps Journal: Haematologica Date: 2016-05-05 Impact factor: 9.941
Authors: Sabine Ponader; Shih-Shih Chen; Joseph J Buggy; Kumudha Balakrishnan; Varsha Gandhi; William G Wierda; Michael J Keating; Susan O'Brien; Nicholas Chiorazzi; Jan A Burger Journal: Blood Date: 2011-12-16 Impact factor: 22.113
Authors: Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy Journal: Proc Natl Acad Sci U S A Date: 2010-07-06 Impact factor: 11.205
Authors: Jennifer A Woyach; Engin Bojnik; Amy S Ruppert; Matthew R Stefanovski; Virginia M Goettl; Kelly A Smucker; Lisa L Smith; Jason A Dubovsky; William H Towns; Jessica MacMurray; Bonnie K Harrington; Melanie E Davis; Stefania Gobessi; Luca Laurenti; Betty Y Chang; Joseph J Buggy; Dimitar G Efremov; John C Byrd; Amy J Johnson Journal: Blood Date: 2013-12-05 Impact factor: 22.113
Authors: Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440
Authors: D J Rawlings; D C Saffran; S Tsukada; D A Largaespada; J C Grimaldi; L Cohen; R N Mohr; J F Bazan; M Howard; N G Copeland Journal: Science Date: 1993-07-16 Impact factor: 47.728
Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps Journal: Blood Date: 2008-01-23 Impact factor: 22.113
Authors: Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245
Authors: Laurens P Kil; Marjolein Jw de Bruijn; Jennifer Ac van Hulst; Anton W Langerak; Saravanan Yuvaraj; Rudi W Hendriks Journal: Am J Blood Res Date: 2013-01-17
Authors: Preetesh Jain; Rashmi Kanagal-Shamanna; F Anthony San Lucas; Loretta Nastoupil; Jorge Romaguera; Luis Fayad; Yasuhiro Oki; Jason R Westin; Leonard Jeffrey Medeiros; Michael Wang; Nathan Fowler Journal: Br J Haematol Date: 2017-08-02 Impact factor: 6.998
Authors: Victor S Lin; Thomas E Lew; Sasanka M Handunnetti; Piers Blombery; Tamia Nguyen; David A Westerman; Bryone J Kuss; Constantine S Tam; Andrew W Roberts; John F Seymour; Mary Ann Anderson Journal: Blood Date: 2020-06-18 Impact factor: 22.113